In-depth Analysis
CLINICAL SHEET
Bone Marrow Aspirate Concentrate (BMAC) in:
MODERATE - TO - SEVERE OSTEOARTHRITIS
Treatment Description
Bone Marrow Aspirate Concentrate (BMAC) is obtained through autologous bone marrow aspiration – typically from the iliac crest – and subsequent mechanical concentration. The final product is rich in multipotent mesenchymal stromal cells (BM-MSCs), progenitor cells, cytokines, growth factors (e.g., TGF-β, VEGF, PDGF), and immunomodulatory components, which exert regenerative activity within the degenerated joint environment.
Biological and Pathophysiological Effects
→ Anti-inflammatory activity through inhibition of pro-inflammatory cytokines (IL-1β, TNF-α) and modulation of local immune responses.
→ Stimulation of cartilage regeneration via paracrine release of growth factors and chondrogenic differentiation of BM-MSCs.
→ Inhibition of cartilage degradation by downregulating matrix metalloproteinases (e.g., MMP-13) and nitric oxide.
→ Analgesic effect due to reduced inflammation and improvement of the intra-articular environment.
Specific Clinical Indications
→ Knee osteoarthritis (grade II–III according to Kellgren-Lawrence classification).
→ Young or middle-aged patients not eligible for early joint replacement.
→ Failure of conservative approaches (HA/corticosteroid injections, physical therapy).
→ Athletes with early cartilage degeneration or persistent joint pain.
Documented Clinical Benefits
→ Significant reduction in joint pain (VAS) within 2–6 weeks post-treatment.
→ Improvement in joint function (WOMAC, KOOS, IKDC), with sustained effects up to 12–24 months in some studies.
→ Potential slowing of radiographic OA progression.
→ Excellent safety profile: no immunogenic reactions, low incidence of infection or persistent donor site pain.
Conclusions
The use of BMAC represents a promising regenerative strategy for the treatment of moderate-tosevere knee osteoarthritis, with documented clinical effects on pain relief and joint function. This biological option is particularly suitable for patients not yet eligible for surgical joint replacement, potentially delaying the need for surgery.
CHRONIC REFRACTORY TENDINOPATHIES
Treatment Description
Autologous Bone Marrow Aspirate Concentrate (BMAC) is a natural source of mesenchymal stem cells (MSCs), bioactive cytokines, growth factors, and immunomodulatory molecules. The treatment involves ultrasound-guided injection of the concentrate into the pathological tendon site.
Biological and Pathophysiological Effects
→ Stimulation of tendon tissue regeneration via growth factor release (PDGF, TGF-β, VEGF).
→ Paracrine MSC signaling promoting angiogenesis and extracellular matrix synthesis.
→ Modulation of chronic inflammation with reduction of pro-inflammatory cytokines.
→ Local antifibrotic and analgesic effects.
Specific Clinical Indications
→ Chronic tendinopathies unresponsive to conservative treatments (e.g., Achilles, patellar tendinopathy, lateral epicondylitis).
→ Active patients or athletes with degenerative tendon lesions.
→ Failed PRP or corticosteroid injections.
Documented Clinical Benefits
→ Tendon structure improvement
→ Pain reduction and improved functional scores (VAS, VISA-A/P).
→ Low complication rate and high safety profile.
→ Potential reduction in recovery time in high-performance athletes.
Conclusions
BMAC therapy offers an innovative biological strategy for resistant tendinopathies, promoting tissue repair and improving function in patients unresponsive to traditional treatments.
ROTATOR CUFF INJURIES
Treatment Description
Bone Marrow Aspirate Concentrate (BMAC), obtained through selective aspiration and mechanical filtration, is rich in mesenchymal stem cells (MSCs), growth factors, cytokines, and hematopoietic cells. It can be used via injection or intraoperatively to support tendon healing.
Biological and Physiopathological Effects
→ Promotes tendon regeneration through MSC paracrine signaling.
→ Reduces local inflammation by modulating pro-inflammatory cytokines (e.g., IL-1β, TNF-α).
→ Enhances angiogenesis in degenerated tissue.
→ Improves bone-to-tendon integration at surgical reattachment sites.
Specific Clinical Indications
→ Partial or full-thickness rotator cuff tears, especially in degenerative tendons.
→ Conservative biologic management in non-surgical candidates.
→ Intraoperative use during arthroscopic or mini-open tendon repair.
Documented Clinical Benefits
→ Pain reduction and functional improvement (UCLA, Constant, ASES scores).
→ Improved quality of regenerated tendon tissue.
→ Lower re-tear rates after surgery
→ High safety profile with no major adverse events.
Conclusions
The use of BMAC in rotator cuff injury management is a promising biologic strategy to enhance tendon healing, improve functional outcomes, and reduce structural failure, particularly in patients with advanced degeneration.
NON-INFECTIOUS SYNOVITIS
Treatment Description
BMAC is used as a biologic treatment in patients with chronic or reactive synovitis. Intra-articular injection delivers MSCs with immunomodulatory and anti-inflammatory properties.
Biological and Physiopathological Effects
→ Modulates synovial immune response.
→ Reduces synovial proliferation and inflammatory cytokine levels.
→ Improves intra-articular microenvironment.
→ Provides secondary protection to cartilage.
Specific Clinical Indications
→ Non-infectious chronic or reactive synovitis.
→ Patients unresponsive to corticosteroid or hyaluronic acid injections.
→ Subacute post-traumatic arthritis.
Documented Clinical Benefits
→ Decreased joint swelling and pain.
→ Improved joint mobility and inflammation control.
→ High tolerability, with no major local/systemic adverse events.
Conclusions
BMAC is a safe and effective biologic option for managing non-infectious synovitis, offering inflammation control and joint functional improvement.
MUSCLE OVERUSE INJURIES
Treatment Description
Bone Marrow Aspirate Concentrate (BMAC) is obtained from autologous bone marrow aspiration, usually from the iliac crest, followed by mechanical separation and concentration. The product contains multipotent mesenchymal stem cells (BM-MSCs), progenitor cells, cytokines, and growth factors (e.g., VEGF, PDGF) with regenerative potential on muscle tissue damaged by repeated mechanical stress.
Biological and Physiopathological Effects
→ Stimulation of neovascularization and cellular proliferation promoting repair of damaged muscle tissue.
→ Reduction of muscle fibrosis through modulation of chronic inflammation induced by repeated microtrauma.
→ Anti-inflammatory and immunomodulatory actions contributing to the improvement of the local microenvironment.
→ Promotion of muscle fiber regeneration and recovery of contractile function.
Specific Clinical Indications
→ Muscle overuse injuries in athletes with chronic pain and functional limitation.
→ Myalgias caused by repeated mechanical stress unresponsive to traditional conservative treatments (rest, physiotherapy, medications).
→ Situations of volumetric muscle loss secondary to overload injuries.
Documented Clinical Benefits
→ Reduction of pain and improvement of muscle strength within 4–8 weeks post-treatment.
→ Faster functional recovery compared to standard rehabilitation protocols.
→ Reduction in recurrence frequency of muscle overuse injuries.
→ Favorable safety profile with minimal incidence of side effects.
Conclusions
The use of BMAC represents a promising therapeutic option for managing muscle overuse injuries in sports medicine, promoting more effective muscle tissue regeneration and reducing functional recovery times in athletes.
AFTER PARTIAL MENISCECTOMY
Treatment Description
Bone Marrow Aspirate Concentrate (BMAC) is obtained through autologous aspiration, usually from the iliac crest, followed by mechanical separation and concentration. The final product is rich in multipotent mesenchymal stromal cells (BM-MSCs), progenitor cells, cytokines, growth factors (e.g., TGF-β, VEGF, PDGF), and immunomodulatory cells, capable of exerting a regenerative effect on the joint environment altered by meniscal resection.
Biological and Pathophysiological Effects
→ Anti-inflammatory activity through inhibition of pro-inflammatory cytokines (IL-1β, TNF-α) and modulation of the local immune response.
→ Modulation of the post-meniscectomy microenvironment to prevent early cartilage degeneration.
→ Stimulation of fibrocartilage regeneration and protection of the remaining meniscal rim.
→ Chondroprotective activity via downregulation of MMPs and nitric oxide (NO).
→ Analgesic effect associated with improved joint homeostasis.
Specific Clinical Indications
→ Partial meniscectomy with persistent pain or biomechanical dysfunction.
→ Early degenerative changes in the articular cartilage following meniscal resection.
→ Young or active patients at risk of rapid chondral deterioration.
→ Failure of conservative postoperative approaches (physiotherapy, analgesics, intra-articular injections).
Documented Clinical Benefits
→ Significant reduction in joint pain (VAS) and inflammatory symptoms within 4–8 weeks post-treatment.
→ Improvement in joint function (WOMAC, KOOS), gait, and activity tolerance.
→ Potential slowing of degenerative progression compared to meniscectomy alone.
→ Excellent safety profile, minimal donor site complications, and no immunogenic reactions
Conclusions
The use of BMAC following partial meniscectomy represents a regenerative strategy aimed at protecting the articular cartilage and enhancing functional recovery. Documented clinical effects support its role in reducing symptoms, improving joint biomechanics, and delaying the onset of osteoarthritis, particularly in young and active patients.